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ABSTRACT
The delivery of radiation therapy to patients requires prior planning made by medical physicists to
achieve radiotherapy goals. Radiotherapy has a plan to eradicate the growth of cancer cells by
giving high doses and minimizing the radiation dose to normal tissue. Evaluation of planning is
generally done based on dosimetric parameters, such as minimum dose, maximum dose, and means
dose obtained from the Dose-Volume Histogram (DVHs) data. Based on the same DVHs, data
were evaluate dinterms of biological effects to determine the highest possible toxicity in normal
tissue after the tumor had been treated with radiation using the Normal Tissue Complication
Probability (NTCP) model. The evaluation was conducted by selecting three DICOM-RT data of
post-mastectomy right breast cancer patients who had been prescribed a dose of 50 Gy obtained
from the Hospital MRCCC Siloam Semanggi database. All data w e r e processed using open-
source software DICOManTX to get the DVH and isodose information. Matlab-based CERR
software was used to calculate the NTCP model. The results show that the three patients' DVH and
isodose treatment planning result in a homogeneous dose distribution result because the PTV area
obtains adose limit of ≥ 95%. Moreover, normalt issue still gets adose below the tolerance limit
based on the standard from RTOG 1005 and ICRU 83. Analysis of NTCP shows a complication
probability below 1% for each organ, suggesting that any organ which has been irradiated has a
low likelihood of complications. Therefore, it can be concluded that the treatment planning which
has been made in the three patients using the IMRT technique has achieved the objectives of
radiotherapy, which is to minimize toxicity to healthy organs.
Keywords: Dose-Volume Histogram, Isodose, Normal Tissue Complication Probability,
Radiotherapy.
INTRODUCTION
Breast cancer is a type of cancer whichoccurs
more frequently than other types of cancer in
women (Ronckers et al., 2005). Recently,
based on data from the American Cancer
Association in 2019 in the United States, it has
been estimated that breast cancer cases
accounted for 268,600 thousand (30%) cases of
new cancer diagnoses and 41,760 thousand
(15%) cases of death in women. In addition,
breast cancer is one of the three most common
cancer cases in women after lung and colon
rectum cancer (Ronckers et al., 2005; Siegel et
al., 2019; Siegel et al., 2019).
Breasts are considered the attribute of
femininity and sexuality for women, so if they
are lost, they can affect a woman's quality of
life (Abebe et al., 2020). Because of this, the
treatment of breast cancer requires
multidisciplinary methods, such as the
combination of surgery and Radiotherapy (RT),
drug therapy as an adjuvant treatment, so that
the treatment goal is achieved (Supakalin et al.,
2018; American Cancer Society, 2021). A
study conducted by Zablotska & Neugut (2003)
explains that breast cancer can cause
metastases to normal tissues, such as the lung,
and trigger the onset of lung carcinoma.
Zablotska investigates mastectomy treatment
and additional RT and reveals that it causes
lung carcinoma to decrease compared to only
giving mastectomy treatment alone with the
number of cases sequentially 345 and 1.885
(Zablotska & Neugut, 2003).
Usually, the treatment used is a
combination of surgery and radiation therapy.
Surgery on breast cancer is divided into two,
namely breast conservation therapy or
lumpectomy and mastectomy or removing the
entire breast and then followed by external
radiotherapy using LINAC (American Cancer
Society, 2021). The choice between
mastectomy and lumpectomy is usually made
under the consideration of an oncologist, and
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the right selection will give long-term
consequences of treatment (Zablotska &
Neugut, 2003).
Postoperative radiation delivery to breast
cancer has been shown to improve patient
survival, compared to surgery alone (Abe et al.,
2005). Based on a study by the Early Breast
Cancer Trialists` Collaborative Group, the
mortality rate from breast cancer with post-
surgical radiotherapy treatment is 40.3%,
compared to that without radiotherapy at
41.4%. This points out that combination
treatment with radiotherapy reduces the
mortality rate after mastectomy or breast
conservation surgery (Early Breast Cancer
Trialists' Collaborative Group, 1995).
RT treatment in postoperative breast cancer
aims to prevent cancer recurrence in the local
area (Harris, 2014). Based on a clinical trial in
2005 by the Early Breast Cancer Trialists`
Collaborative Group (EBCTCG), RT not only
reduces cancer recurrence in the local area, but
also inhibits metastasis. However, providing
RT care is a challenge for a medical physicist
because of the presence of OARs (Organs at
Risk) around the breasts, coupled with the
motion of the lung and heart. Therefore, the RT
treatment planning system has tobe made
accurately to meet the target volume to be
irradiated for maximum dose and
homogeneous dose distribution, while at the
same time minimizing radiation in OARs
(Pyakuryal et al., 2010).Modern techniques
commonly used in the treatment of RT are 3-
Dimension Conformal Radiotherapy (3D-
CRT), Intensity-Modulated Radiation Therapy
(IMRT), and Image-Guided Radiation Therapy
(IGRT) (Pyakuryal et al., 2010). Based on
RTOG 1005, the IMRT technique leads toan
increased dose distribution in the breast, where
as in OARs, such as the lung and heart,it
generates low doses and indicates low toxicity
(Chui et al., 2002; Freedman et al., 2006;
Rudra et al., 2014; Vicini et al., 2002). In
addition, (Harsolia et al., 2007) also report that
the IMRT technique reduces the significant
presence of acute dermatitis, edema, and
hyperpigmentation, compared to conventional
wedge-based radiation techniques.
Traditionally, the RT plan's qualityis based
on the dose limit value in OARs and the mean
doseof each (Region of Interest) ROI when
referring to the RTOG. To that end, ICRU
reports 83 guidelines. The RT plan will be
more effective if it is evaluated in terms of
physical dosimetry and biological effects.
Because the endpoint of radiotherapy is not the
dose distribution, it is essential to investigate
how likely it is to control the tumor in the local
area. This is known as the Tumor Control
Probability (TCP) and Normal Tissue
Complications Probability (NTCP) (Nahum,
1996).
Evaluation of this biological effect aims to
maximize TCP and minimize the NTCP
(Nahum, 1996). These two radiobiological
parameters show the toxicity which affects
normal tissue after radiation. Tapping into the
evaluation treatment planning on breast cancer,
this study will evaluate the IMRT treatment
planning system in post-mastectomy breast
cancer cases based on biological response
using radiobiological models, namely TCP and
NTCP. The evaluation results are projected to




Three Digital Imaging and Communications in
Medicine Radiotherapy (DICOM-RT) datasets were
selected from the MRCCC Siloam Semanggi
Hospital database, labeled as ID1, ID2, and ID3. The
selection process was based on mastectomy breast
cancer (breast that has been removed). The tumor
cells were located in the right breast. The
prescription dose was 50 Gy with a daily dose of 2
Gy, and the treatment planning system employed
IMRT techniques. The treatment planning system
for RT was carried out using 6 MV photons with
Eclipse 2300 CD Varian linear accelerator.
Modeling of Dose Volume Histogram and
Isodosis Lines
DICOManTX was used to analyze the Dose-Volume
Histogram (DVH) and isodose line for all DICOM-
RT data (Yan et al., 2013). Before the DVH
modeling process, the beam's doses in the Treatment
Planning System (TPS) were accumulated into one
accumulated dose. The accumulated dose was then
modeled on a DVH curve to see the dose
distribution using the DVH menu. Meanwhile, the
isodose line was calculated by multiplying the dose
from 5 Gy to 50 Gy.
Biological Model in Plan Optimization
NCTP values were used to guide clinical decisions,
and this modeling used the Lyman Kutcher-Burman
(LKB) model (Li et al., 2012; Kutcher & Burman,
1989). NCTP modeling with the LKB model was
carried out on OARs, such as lung, heart, liver,
spinal cord, and trachea. NTCP value was assumed
to be a sigmoid relationship between carcinoma and
Equivalent Uniform Dose (EUD)(Seppenwoolde et
al., 2003). The LKB model can be represented
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mathematically by the probit function expressed in
equation (1):NCTPLKB= 1√2π exp -u22 dut-∞
= 12 1+ erf t√2 (1)
where t is the upper limit of integrals obtained from
the equation (2), t= gEUD-TD50mTD50 (2)gEUD= vivtot diai
1/a (3)
The LKB model was generated based on the
concept of general uniform dose (gEUD)/EUDLKB,
which has been called effective dose, homogeneous
dose, and EUD. d refers to the dose and is the
volume irradiated with dose . The LKB model
consists of three parameters, namely TD50, m, and
a=1/n. TD50 represents dose (or relative damaged
volume) administered to all organs resulting in a
complication of 50%. is the local dose for 50%
local damage.m is the gradient of the LKB model
curve (the curve increasing with decreasing m).
a=1/n denotes tissue-specific parameter which
explains the volume effect. There are three
parameters for the volume effect, including (a <-10)
for tumor, (a >10) for a serial-respond
complication, and (a~1) for parallel-response
complication. Then value n = 1 indicates sensitivity
to a volume at the highest dose, while the n value
closer to 1 indicates that the response is due to the
average effect across organs (Marks et al., 2010).
The value of NCTP for all risk organs was
calculated using open-source CERR software
(Deasy et al., 2003) with in-house Matlab software.
Therefore, all DICOM-RT data before calculating
NCTP with the LKB model had to be
converted into the Matlab / CERR format to analyze
the NCTP value.
RESULTS AND DISCUSSION
In this study, three patients with post-
mastectomy right breast cancer were treated
using the IMRT technique with a total dose of
50 Gy in 25 fractionations. The treatment was
analyzed based on dosimetric analysis and
biological parameters. The dosimetric analysis
is based on the minimum dose and the mean
dose values obtained from the DVH
accumulation, while the biological parameters
correspond to the NTCP value. The IMRT
technique based on RTOG 1005 and ICRU 83
is a modulated radiation delivery technique
which allows normal, sensitive tissue to obtain
a low dose with a fixed target volume to obtain
the maximum dose. However, other obstacles
in taken into account in planning treatment,
especially in breast cancer, because the breast
area is close to the heart and lungs, which
continuously move so that their position is not
always fixed. Therefore, this circumstance
requires proper and accurate treatment
planning. An optimal treatment planning will
have a low-risk toxic effect on organs after
radiation exposure.
Figure 1. The three types of DVHs in the PTV area produced from the DICOManTX software with
the sequence of post-mastectomy breast cancer patients are: a. ID 1, b. ID 2 and c. ID 3.
a b
c
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Figure 2. Results of isodose 2D using DICOManTX software in all 3 post-mastectomy breast
cancer patients, a. patient ID 1, b. patient ID 2 and c. patient ID 3
DVH analysis and isodose distribution are
complementary parameters for evaluating
treatment planning systems based on biological
models. Evaluating planning calls for more
than the parameters involving mean dose,
maximum dose, and minimum dose because
these parameters may look similar in several
treatment plans but differ in radiobiological
results (Lee et al., 2015). The DVH analysis
results demonstrate whether the dose
distribution in OARs is within tolerance limits
or not and whether the target volume is 100%
covered by the dose (Das et al., 2017).
The DVH clinical data shown in Figure 1
were obtained using the DICOM-RT data
belonging to MRCCC Siloam Hospital
Semanggi, which was processed using the
software DICOManTX. Based on the RTOG
1005 report for the evaluation of PTV, ideally,
the dose distribution should cover ≥ 95% of the
total dose given. This means that if the total
dose given is 50 Gy, PTV has to obtain ≥ 47.5
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The three patients (ID 1, ID 2, and ID 3) in
Table 1 indicatethe dosimetry results as shown
by mean dose in the target area (PTV) of 50.88
Gy, 50.49 Gy, and 50.08 Gy, respectively.
Based on the mean dose results on PTV, a
treatment planning system using the IMRT
technique in three patients appear to have
achieved the desired dose. Meanwhile, OARS,
such as the heart and lungs, have also marked
the dose tolerance limits allowed by the RTOG
protocol. Based on the RTOG 1005 protocol,
the heart can tolerate a maximum mean dose of
≤ 26 Gy, and the lung's limit is ≤ 35% of the
dose, which is equal to ≥ 10 Gy. Table 2 shows
the results of the dose received by the organ at
risk closest to the breast/target volumeusing the
reference from RTOG 1005. In the heart, it
appears that all patients receivedoses below the
threshold, meaning that the risk of damage to
the heart due to radiation is relatively low.
Furthermore, the lung is also the same where
the lung's dose is still below the dose threshold.
If the dose exceeds the threshold, pneumonitis
symptoms in the lungs and pericarditis in the
heart may occur.












ID 1 37.58 50.88 52.93 1.31
ID 2 36.00 50.49 55.13 1.43
ID 3 13.80 50.08 53.98 1.79
Table 2. Tolerance limit in OARs based on the
accumulation DVHs
ROI ID 1 ID 2 ID 3
Heart
Mean dose ≤ 26 Gy 0.62 Gy 13.9 Gy 8.49 Gy
Lung Right
V20 ≤  35% 11.9 % 17.67% 24.68%
The isodose line was used to explain the
dose distribution results on OARs, as shown in
Figure 2. Isodose is used to see how wide the
dose distribution coverage is in relation to the
volume target and organs at risk. The isodose
line in Figure 2 is expressed in a relative dose
range of 20 - 100%. For the volume obtained,
the highest dose level was 100% (50 Gy), and
the lowest dose level was 20% (10 Gy).
Based on Figure 2 (a, b, c), it can be seen
thatthe IMRT technique generates an isodose
line pattern whichadjusts to the volume target.
Figure 2 (a, b, c) also shows that the
distribution of the highest dose at 100% covers
all areas of PTV, and the further away from
PTV, the dose level decreases so that OARs,
such as the heart andlungs, still receive
radiation doses within safelimits. Hence, it can
be indicated that the dose distribution in the
CTV and PTV areas is homogeneous.
Breast cancer from three patients occurred
in the right breast area so that the right lung
received more radiation than the left lung.Even
though this area was exposed to more radiation,
it was still below the threshold; this is
supported by the results presented in Table 2.
Table 2 shows that the heart is still treated
underthe tolerable dose category because the
mean dose absorbed by the heart does not
exceed 26 Gy. The isodose parameter makes it
easier to see the dose homogeneity when it hits
the target; this homogeneity will later lead to
more possibilities in controlling the tumor,
which has fewer side effects on the skin and
lungs. Based on the value of DVH and isodose,
it can be concluded that treatment planning for
the three breast cancer patients is acceptable,
but DVH and isodose are still insufficient to
evaluate the possible toxicity levels in healthy
organs after radiation.
Administering several beams of radiation
over a specific time will cause acute toxicity in
several organs. Excessive toxicity can cause
death in organs. To prevent toxicity, it is
necessary to investigate the possibility of
complications in normal tissue, analyzed from
DVH data. Evaluation based on parameters
radiobiological can be obtained through a
biological model, i.e., NTCP.
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Spinal Cord 3.3923 0.077641
Trachea 15.5305 0.32944









Spinal Cord 7.4268 0.13665
Trachea 13.1897 0.26423









Spinal Cord 2.9037 0.072069
Trachea 4.4859 0.09129
Figure 3. Sigmoid curve between the percentages of NTCP to the value of the EUD (Gy) in patient
ID 1 with a. lung, b. heart, c. spinal cord, d trachea
a. Lung b. Heart c. Spinal Cord d. Trachea
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Figure 4. Sigmoid curve between the percentages of NTCP to the value of the EUD (Gy) in patient
ID 2 with a. lung, b. heart, c. spinal cord, d trachea
Figure 5. Sigmoid curve between the percentages of NTCP to the value of the EUD (Gy) in patient
ID 3 with a. lung, b. heart, c. spinal cord, d trachea
NTCP is part of the evaluation treatment
planning and plays essential rolein clarifying
dosimetric information before complex
anatomy becomes a risk (Marks et al., 2010).
Evaluation of dose distribution at target volume
and critical structure is based not only on
absorbed dose and volume, but also on
radiobiological models such as NTCP. The
NTCP model can help improve optimal
treatment planning (Tommasino et al., 2017).
NTCP results have been presented in
Tables 3, 4, and 5, the data of which are
obtained using the DICOManTX software. The
NTCP value is calculated using LKB model
according to formula (1). Tables 3, 4, and 5
present the value of possible complications in
normal organs after radiation exposure. Based
on the NTCP value, it is known that for normal
organs (lung, heart, spinal cord, and trachea)
around the target volume, the chance of
complications after radiation is minimal
because the NTCP value is less than 1. The
NTCP value results in this study resonate with
the study conducted by (Marks et al., 2010),
which explains thata complication value equal
to 1 denotes possible complication in large
parallel organs or large volumes. More details
can be seen from the curve between the EUD
value against NTCP in Figures 3, 4, and 5.
These values show that all OARs for
complications are small because the average
range of NTCP values for each organ is 0.32 -
0.077 or less than 1. The EUD value on the
curve also represents something similar to
DVH, which means higher EUD value results
in an increased probability of complications in
healthy organs.
CONCLUSION
In this study, evaluation of treatment planning
performed using the IMRT technique in
patients ID 1, 2, and 3 with right breast cancer
post-mastectomy has achieved radiotherapy
objectives according to ICRU 83 and RTOG
1005. Based on the dosimetric analysis of the
a. Lung b. Heart c. Spinal Cord d. Trachea
a. Lung b. Heart c. Spinal Cord d. Trachea
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results of the DVH, isodose, and biological
parameters of the NTCP value, the treatment
plan made shows a homogeneous dose
uniformity in the volume target area. In
addition to producing a uniform dose
distribution, this evaluation also shows that the
NTCP value for each organ is less than 1,
which means that the probability of
complications after radiation therapy is small.
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